Left Ventricular Free-wall Ruptrue After Acute Myocardial Infarction (LVFR-AMI)

March 31, 2021 updated by: Yan Wang, Xiamen Cardiovascular Hospital, Xiamen University

Clinical Characteristics of Left Ventricular Free-wall Ruptrue After Acute Myocardial Infarction

The Left Ventricular Free-wall Ruptrue (LVFR) is a serious complication caused high mortality.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The actual mortality of LVFR is close to 100%. Despite the mortality rate for LVFR has been decreasing with the development of reperfusion therapy, the serious complication remains a difficult challenge. The coronary anatomy distribution associated with LVFR has an interesting phenomenon. From the perspective of different coronary distribution, we can better known the risk factors related to LVFR.

Study Type

Observational

Enrollment (Anticipated)

17568

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Fujian
      • Xiamen, Fujian, China, 361000
        • Recruiting
        • Xiamen Cardiovascular Hospital Xiamen University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study population of acute myocardial infarction (STEMI or NSTEMI) patients.

Description

Inclusion Criteria:

  • Patients be admitted for acute myocardial infarction (STEMI or NSTEMI)

Exclusion Criteria:

  • Non-cardiovascular comorbidity for AMI

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Heart rupture
Include left ventricular free-wall ruptrue after AMI
Diagnostic test: Heart rupture
Left ventricular free-wall ruptrue after AMI
Non heart rupture
AMI with non heart rupture

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of heart ruputre
Time Frame: Mortality 30 days
Left Ventricular Free-wall Ruptrue
Mortality 30 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of cardiogenic shock
Time Frame: Hospitalization 30 days
Cardiogenic shock After AMI
Hospitalization 30 days
Rate of cardiac arrest
Time Frame: Hospitalization 30 days
Cardiac arrest After AMI
Hospitalization 30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Xiamen Cardiovascular Hospital, Xiamen University

Investigators

  • Study Chair: Yan Wang, PhD, Cardiovascular Hospital, Xiamen University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2011

Primary Completion (Actual)

December 31, 2019

Study Completion (Anticipated)

March 31, 2021

Study Registration Dates

First Submitted

November 18, 2019

First Submitted That Met QC Criteria

November 18, 2019

First Posted (Actual)

November 21, 2019

Study Record Updates

Last Update Posted (Actual)

April 1, 2021

Last Update Submitted That Met QC Criteria

March 31, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 9215443689

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Myocardial Infarction

Clinical Trials on Heart rupture

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe